We are live on ! Find out more
SWTX

SpringWorks Therapeutics
SWTX

Delisted

SWTX was delisted on the 30th of June, 2025.

Back to rankings

142 hedge funds and large institutions have $1.82B invested in SpringWorks Therapeutics in 2023 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 68 increasing their positions, 36 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

89% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 36

7% more capital invested

Capital invested by funds: $1.7B → $1.82B (+$120M)

5.34% more ownership

Funds ownership: 106.03% → 111.38% (+5.3%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

4% less funds holding

Funds holding: 148 → 142 (-6)

20% less call options, than puts

Call options by funds: $951K | Put options by funds: $1.2M

26% less first-time investments, than exits

New positions opened: 14 | Existing positions closed: 19

Holders
142
Holders Change
-6
Holders Change %
-4.05%
% of All Funds
2.23%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
14
Increased
68
Reduced
36
Closed
19
Calls
$951K
Puts
$1.2M
Net Calls
-$244K
Net Calls Change
-$7.01M

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$28M
2
Marshall Wace
Marshall Wace
United Kingdom
+$26.9M
3
BlackRock
BlackRock
New York
+$26.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$13M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$12.2M

Top Sellers

Rank Fund Capital Flow
1
WP
Woodline Partners
California
-$34.2M
2
PA
Perceptive Advisors
New York
-$14.2M
3
Barclays
Barclays
United Kingdom
-$14.1M
4
Victory Capital Management
Victory Capital Management
Texas
-$13.3M
5
O
OrbiMed
New York
-$8.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$13.1M +$4.21M +160,119 +47%
Massachusetts Financial Services
27
Massachusetts Financial Services
Massachusetts
$12.5M -$118K -4,477 -0.9%
ITP
28
Iron Triangle Partners
Connecticut
$12.2M +$4M +152,271 +49%
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$12.2M +$12.2M +463,611 +121,683%
LCM
30
Laurion Capital Management
New York
$9.94M -$490K -18,632 -5%
Charles Schwab
31
Charles Schwab
California
$9.56M +$1.4M +53,247 +17%
Morgan Stanley
32
Morgan Stanley
New York
$8.94M +$341K +12,969 +4%
SFM
33
Sphera Funds Management
Israel
$8.2M -$131K -5,000 -2%
Norges Bank
34
Norges Bank
Norway
$7.02M – – –
New York State Common Retirement Fund
35
New York State Common Retirement Fund
New York
$6.54M +$1.73M +65,872 +36%
Jane Street
36
Jane Street
New York
$6.37M +$4.95M +188,314 +346%
Bessemer Group
37
Bessemer Group
New Jersey
$6.33M – – –
Rafferty Asset Management
38
Rafferty Asset Management
New York
$6.31M +$578K +21,982 +10%
Ameriprise
39
Ameriprise
Minnesota
$5.85M -$753K -28,665 -11%
Bank of New York Mellon
40
Bank of New York Mellon
New York
$5.78M +$2.45M +93,143 +73%
MCM
41
M28 Capital Management
Connecticut
$5.18M – – –
Voloridge Investment Management
42
Voloridge Investment Management
Florida
$5.04M -$4.17M -158,544 -45%
D.E. Shaw & Co
43
D.E. Shaw & Co
New York
$4.46M -$3.59M -136,498 -45%
PCM
44
Peregrine Capital Management
Minnesota
$4.44M -$1.31K -50 -0%
Wells Fargo
45
Wells Fargo
California
$4.01M +$1.22M +46,382 +44%
CS
46
Candriam SCA
Luxembourg
$3.95M +$3.66M +139,136 +1,211%
N
47
Nuveen
North Carolina
$3.86M +$1.59M +60,573 +70%
WP
48
Woodline Partners
California
$3.85M -$34.2M -1,300,389 -90%
AAA
49
Affinity Asset Advisors
New York
$3.41M +$3.42M +130,000 New
Barclays
50
Barclays
United Kingdom
$3.19M -$14.1M -536,105 -81%
1
2
3 4 5

SWTX Hedge Fund Activity: Q2 2023 in Review

142 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in SpringWorks Therapeutics (SWTX) for Q2 2023, worth a combined $1.82B — up 7% from $1.7B a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of SWTX and 14 opened new positions — a net loss of 5 holders — while 36 trimmed existing stakes and 68 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $28M. The largest seller was Woodline Partners, cutting an estimated $34.2M.

  • 142 institutional investors held SpringWorks Therapeutics (SWTX) as of Q2 2023, down from 148 in Q1 2023.
  • Funds reported $1.82B of SpringWorks Therapeutics stock for Q2 2023, up 7% quarter-over-quarter.
  • 14 funds opened new SpringWorks Therapeutics positions in Q2 2023 and 19 closed out, a net change of -5 holders.
  • The largest SpringWorks Therapeutics buyer in Q2 2023 was T. Rowe Price Associates, an estimated $28M added.
  • The largest SpringWorks Therapeutics seller in Q2 2023 was Woodline Partners, an estimated $34.2M sold.

Based on aggregated 13F filings for Q2 2023.